Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial) — Stella
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
(18 sites) Poland
University Clinical Hospital in Bialystok, Bialystok Nicolaus Copernicus University Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz Medical University of Gdansk, Gdansk Regional Specialist Hospital in Grudziadz, Grudziądz Upper-Silesian Heart Center, Katowice John Paul II Hospital, Krakow Medical University of Lodz, Lodz Zbigniew Religa Heart Center "Medinet", Nowa Sól Provincial Specialist Hospital in Olsztyn, Olsztyn Institute of Medical Sciences in Opole, Opole J. Struś Hospital, Poznan Poznan University of Medical Sciences, Poznan Pomeranian Medical University, Szczecin Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw Medicover Hospital, Warsaw Wroclaw Medical University, Wroclaw Zbigniew Religa Heart Center "Medinet", Wroclaw Silesian Centre for Heart Diseases in Zabrze, Zabrze
Key details Sponsor
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.
Collaborators
Medical Research Agency, Poland
Enrollment target
~1,703 participants
Primary completion
April 2030
Age range
18 Years and older
Last updated January 2026